article thumbnail

Researchers develop CRISPR-based drug candidate for microbiome targeting

Pharmaceutical Technology

Blood cancer patients with E coli infection are at risk of bacteria infecting the bloodstream. The research team has designed four bacterial viruses which use CRISPR technology to kill the unwanted bacteria precisely. The team then engineered the phages through gene editing to improve their targeting ability.

article thumbnail

Gene-editing produces tenfold increase in superbug slaying antibiotics

Scienmag

Martins Scientists have used gene-editing advances to achieve a tenfold increase in the production of super-bug targeting formicamycin antibiotics. The John Innes Centre researchers used the technology to create a new strain of Streptomyces formicae bacteria which over-produces the medically promising molecules.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Johns Hopkins Researchers Identify CRISPR Dimmer

BioSpace

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell, could have implications for gene editing therapies as well.

article thumbnail

Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal

pharmaphorum

CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to develop, manufacture and market a gene editing therapy for sickle cell disease and beta thalassemia.

article thumbnail

CRISPR pioneers Doudna and Charpentier claim Nobel chemistry prize

pharmaphorum

Drs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their work on the gene-editing technology CRISPR/Cas9. Charpentier’s early work in this area led to the discovery of tracrRNA, a previously unknown molecule that defends bacteria from viruses by cleaving their DNA.

article thumbnail

CRISPR Therapeutics begins natural killer cell cancer tie-up with Nkarta

pharmaphorum

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. It’s at the forefront of gene editing although the technology has spawned rivals including Intellia Therapeutics, Caribou Biosciences, Sangamo Therapeutics and Mammoth Biosciences.

article thumbnail

Gene Therapy and Pharmacokinetics

Camargo

Gene therapy is a new therapeutic approach in which genes are used to treat or prevent diseases. It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy.